Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Kiel – page 26

434 clinical trials in Kiel, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Kiel at a glance
434
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

434 trials in Kiel

Open in trial search

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Comparison of Post-Transplant Cyclophosphamide versus Anti-T Lymphocyte Immunoglobulin for Prevention of Graft versus Host Disease in Patients Receiving Unrelated Donor Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:DKMS Group gGmbH

Study on the Effects of Sonelokimab for Patients with Moderate-to-Severe Palmoplantar Pustulosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Rectal cancer

Not recruiting

Study Comparing Short Course Radiotherapy and Chemoradiotherapy with Fluorouracil, Calcium Folinate, and Capecitabine for Intermediate and High-Risk Rectal Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Goethe University Frankfurt

Neoplasm

Not recruiting

Study of Vusolimogene Oderparepvec and Nivolumab for Patients with Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Replimune Group Inc.

Parkinson's disease

Not recruiting

Study on the Safety and Effects of Fasudil Hydrochloride for Patients with Parkinson's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fasudil Hydrochloride
  • Sponsor:Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Breast cancer

Not recruiting

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Universitaetsklinikum Regensburg AöR

Palliative care

Not recruiting

Study on Improving Quality of Life in Cancer Patients Using Dronabinol and Cannabidiol

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Cannabidiol
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Goethe University Frankfurt

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Kiel

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies of ribociclib with endocrine therapy for HR-positive, HER2-negative cases. Additional research encompasses various blood cancers, including lymphomas and leukemia.

  • Early-stage breast cancer therapy
  • Diffuse large B-cell lymphoma treatments
  • Acute myeloid leukemia management

Cutting-edge research evaluating novel therapeutic combinations and treatment approaches for better patient outcomes.

02 Dermatological Studies

Comprehensive research into chronic skin conditions, including trials for plaque psoriasis and atopic dermatitis. Studies evaluate new therapeutic agents for moderate to severe cases.

  • Hidradenitis suppurativa treatments
  • Novel psoriasis therapies
  • Atopic dermatitis management

Focus on developing effective treatments for persistent skin conditions that significantly impact quality of life.

03 Gastrointestinal Research

Advanced studies in inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. Trials investigate innovative therapies for moderate to severe cases.

  • Long-term disease management
  • Combination therapy approaches
  • Treatment-resistant cases

Investigation of new therapeutic options for patients with inadequate response to conventional treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.